Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GS 030

Next Previous
X
Search
Drug Profile

GS 030

Alternative Names: AAV2.7m8-ChrimsonR-tdTomato; ChrimsonR-tdT; GS-030; GS030 DP; GS030-MD; rAAV2.7m8-ChrimsonR-tdT

Latest Information Update: 15 Feb 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GenSight Biologics
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Opsin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Retinitis pigmentosa
  • Preclinical Age-related macular degeneration

Most Recent Events

  • 13 Feb 2023 Efficacy and adverse events data from the phase I/II PIONEER trial in Retinitis pigmentosa released by GenSight Biologics
  • 16 Dec 2022 Preclinical trials in Age-related macular degeneration in France (Intravitreous) (GenSight Biologics pipeline, December 2022)
  • 16 Dec 2022 GenSight Biologics plans a phase I/II trial for Age-related macular degeneration in 2024 (GenSight Biologics pipeline, December 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top